» Authors » Hideki Fujii

Hideki Fujii

Explore the profile of Hideki Fujii including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 539
Citations 10896
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Arai T, Hayashi E, Maeda S, Matsubara T, Fujii H, Shinohara K, et al.
Nat Commun . 2025 Mar; 16(1):1950. PMID: 40082404
Compensatory pancreatic islet hyperplasia is an adaptive response to increased systemic insulin demand, although factors meditating this response remain poorly understood. Here, we show that a liver-derived secreted protein, Neuregulin1α,...
2.
Goto S, Hamano T, Taniguchi M, Abe M, Nitta K, Nishi S, et al.
Sci Rep . 2025 Mar; 15(1):8089. PMID: 40057535
In hemodialysis patients, it remains unclear whether patient characteristics influence the clinical impacts of changes in serum mineral metabolism parameters on mortality. In this 9-year cohort study, we investigated the...
3.
Imai E, Imai A, Izumi M, Nakazawa J, Fujii H, Nishi S
Intern Med . 2025 Feb; PMID: 39971290
Collagenofibrotic glomerulopathy is a rare, incurable kidney disease characterized by severe proteinuria and extensive type III collagen deposition in mesangial and subendothelial spaces. To date, no effective treatment has yet...
4.
Akizuki M, Murakami K, Sekine K, Murakami A, Kobayashi K, Matsuda M, et al.
J Appl Microbiol . 2025 Feb; 136(2). PMID: 39963719
Aims: To prevent peri-implantitis, we investigated the adhesion of periodontopathogenic bacteria to titanium surfaces using a hydrophobic 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer to inhibit adhesion. Method And Results: We immersed titanium...
5.
Ishiba H, Fujii H, Kamada Y, Sumida Y, Takahashi H, Seko Y, et al.
Hepatol Commun . 2024 Dec; 9(1). PMID: 39670882
Background: Various noninvasive tests can be used to identify high-risk groups of patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD). In this study, we compared the diagnostic performance of serum...
6.
Kamada Y, Sumida Y, Takahashi H, Fujii H, Miyoshi E, Nakajima A
J Gastroenterol . 2024 Dec; 60(1):10-23. PMID: 39652103
Mac-2 binding protein glycosylation isomer (M2BPGi) is a liver fibrosis biomarker that originated in Japan and has been covered by health insurance for 10 years. M2BPGi is useful not only...
7.
Kamada Y, Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, et al.
Gastro Hep Adv . 2024 Nov; 3(8):1148-1156. PMID: 39559296
Background And Aims: The clinical characteristics and risk factors involved in the development of liver fibrosis in the subtypes of steatotic liver disease (SLD) remain unknown. We examined the clinical...
8.
Kawanaka M, Kamada Y, Takahashi H, Iwaki M, Nishino K, Zhao W, et al.
Gastro Hep Adv . 2024 Nov; 3(8):1120-1128. PMID: 39533978
Background And Aims: Although numerous noninvasive diagnostic methods have been developed to predict liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), they lack markers for predicting lobular inflammation, hepatocellular...
9.
Asano K, Kageyama K, Yamamoto A, Jogo A, Nakano M, Murai K, et al.
Cancer Med . 2024 Nov; 13(21):e70367. PMID: 39487694
Aim: The purpose of this study was to evaluate the predictors of deterioration of the Child-Pugh classification 1 month after transcatheter arterial chemo-embolization (TACE) in patients with treatment-naive hepatocellular carcinoma...
10.
Takeuchi K, Yamaguchi K, Takahashi Y, Yano K, Okishio S, Ishiba H, et al.
Sci Rep . 2024 Oct; 14(1):23993. PMID: 39402176
GDF15 and FGF21, stress-responsive cytokines primarily secreted from the liver, are promising therapeutic targets for metabolic dysfunction-associated steatotic liver disease (MASLD). However, the interaction between GDF15 and FGF21 remains unclear....